论文部分内容阅读
目的:评价阿米福汀联合腹腔灌注化疗治疗难治性及复发性卵巢癌疗效分析。方法:本研究纳入难治性及复发性卵巢癌患者共计68例,试验组36例,对照组32例,两组采用相同的化疗方案,试验组加用阿米福汀。治疗结束后评价疗效,并在治疗前后分别检测患者的毒性反应及相关指标的变化情况。结果:试验组治疗前后及试验组和对照组治疗后分别进行Karnofsky评分比较,发现试验组治疗后明显改善患者的体力状况(P<0.000 1);虽然试验组近期有效率高于对照组,但无统计学意义;但是试验组化疗期间产生骨髓抑制、肝肾毒性与对照组相比明显减轻;恶心呕吐症状试验组明显高于对照组,比较有统计学意义(P<0.05)。结论:本研究应用阿米福汀联合腹腔化疗治疗难治性及复发性卵巢癌明显降低毒副作用,同时全身症状明显得到改善。
Objective: To evaluate the efficacy of amifostine combined with intraperitoneal perfusion chemotherapy in the treatment of refractory and recurrent ovarian cancer. METHODS: A total of 68 patients with refractory and recurrent ovarian cancer were enrolled in this study, 36 in the trial group and 32 in the control group. The same chemotherapy regimen was used in both groups, with amifostine in the trial group. The curative effect was evaluated after the treatment, and the changes of the patients’ toxic reactions and related indexes were detected before and after the treatment. Results: Compared with Karnofsky score before and after treatment in experimental group and control group, Karnofsky score was significantly improved in experimental group after treatment (P <0.000 1). Although the effective rate in experimental group was higher than that in control group, No significant difference was found between the two groups. However, myelosuppression was induced during the chemotherapy in the experimental group, and liver and kidney toxicity was significantly reduced compared with the control group. The nausea and vomiting symptom test group was significantly higher than the control group (P <0.05). Conclusion: In this study, the application of amifostine combined with intraperitoneal chemotherapy in the treatment of refractory and recurrent ovarian cancer significantly reduced the side effects and systemic symptoms were significantly improved.